Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.

@article{Michaelis2006OngoingIV,
  title={Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.},
  author={Mary L. Michaelis and Gunda I. Georg and Hanumaiah Telikepalli and Mark A. McIntosh and Roger A. Rajewski},
  journal={Current Alzheimer research},
  year={2006},
  volume={3 3},
  pages={215-9}
}
Most drug discovery efforts for Alzheimer's disease (AD) have focused on prevention or clearance of beta-amyloid (Abeta) fibrils or oligomers, with far less attention to prevention of tau abnormalities that lead to neurofibrillary tangles (NFTs). Much evidence now indicates that Abeta multimers can trigger neurodegenerative changes that involve formation of dystrophic neurites and cytoskeletal collapse, possibly due loss of microtubule (MT) stabilization by the tau protein. We have found that… CONTINUE READING

Similar Papers

Loading similar papers…